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Abstract
The MAGE (melanoma associated antigen) protein family are tumour-associated proteins
normally present only in reproductive tissues such as germ cells of the testis. The human
genome encodes over 60 MAGE genes of which one class (containing MAGE-A3 and
MAGE-A4) are exclusively expressed in tumours, making them an attractive target for the
development of targeted and immunotherapeutic cancer treatments. SomeMAGE proteins
are thought to play an active role in driving cancer, modulating the activity of E3 ubiquitin
ligases on targets related to apoptosis. Here we determined the crystal structures of MAGE-
A3 and MAGE-A4. Both proteins crystallized with a terminal peptide bound in a deep cleft
between two tandem-arranged winged helix domains. MAGE-A3 (but not MAGE-A4), is pre-
dominantly dimeric in solution. Comparison of MAGE-A3 and MAGE-A3 with a structure of an
effector-bound MAGE-G1 suggests that a major conformational rearrangement is required for
binding, and that this conformational plasticity may be targeted by allosteric binders.
Introduction
MAGE genes were first identified as antigens recognized by cytolytic T lymphocytes from a
MZ-2 human melanoma cell line [1], and due to the fact that in many cases their expression is
strictly limited to tumour cells, are considered attractive targets for immunotherapeutic treat-
ment of a broad spectrum of cancer types. Subsequent work has established the existence of
more than 60 MAGE family proteins in humans which have been further classified based on
expression pattern into two classes, class I being expressed exclusively in malignant tumours
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and male germ cells, whilst class II being expressed ubiquitously in normal adult human cells
[2]. Further classification of MAGE genes into subfamilies has been performed based on chro-
mosomal clustering with class I constituting 15 MAGE-A genes, 17 MAGE-B genes and 7
MAGE-C genes all clustered to discrete locations on the X chromosome [3]. The silenced
expression of proteins in the class I MAGE family genes in normal adult cells is thought to be
achieved in some cases by CpG methylation of Ets consensus sites within the promoters [4],
and this silencing was found to be reversed in a broad spectrum of tumours due to DNA hypo-
methylation [5]. All MAGE family members contain a shared core MAGE homology domain
(MHD) which is a ~ 200 amino acid long domain, which is well conserved across the entire
MAGE family (individual human MHD’s share more than 40% sequence identity). In addition
to the MHD both N-terminal and C-terminal domains are present, which show little sequence
similarity beyond their immediate subfamily neighbours. Evolutionary analysis suggests that
class I MAGE proteins are under positive selection pressure and have diversified in the homi-
nin lineage to acquire additional functions [6].
MAGE-A3 and MAGE-A4 are two of the better studied members of the MAGE family due
to their promising status as targets for cancer diagnosis, prognosis and immunotherapy. Both
genes are strongly expressed in various cancer types, with MAGE-A3 expression observed in 60%
of malignant melanomas [7], 45% of non-small-cell lung carcinomas (NSCLC) [8], 70% of
Durie-Salmon stage III multiple myelomas [9] and 37% of bladder cancers [10]. MAGE-A3 was
more commonly detected in metastatic (76%) vs primary (36%) melanoma lesions [7], and in
relapsed (77%) vs newly diagnosed, untreated (36%) multiple myeloma cases [11]. MAGE-A3
expression by immunohistochemistry or gene expression profiling was associated with poorer
outcome in NSCLC and multiple myeloma [8, 12]. MAGE-A4 is expressed in 38% of nonmuscle-
invasive bladder carcinoma tumours, 48% of muscle invasive tumours, 65% of carcinomas in situ
and 73% of lymph node metastases [13]. Although these findings in primary tumours suggest a
pathogenic role for class I MAGE in cancer, until recently it was not clear whether they are “driv-
ers” or “passengers” of the tumorigenic process. It is now apparent that class I MAGE are likely
to be oncogenes that promote growth and survival of tumour cells. Expression of MAGE-A3 and
MAGE-A6 (a protein that is almost identical in sequence (98% identity), chromosomal location
and expression to MAGE-A3) was sufficient to drive the transformation of human colonic epi-
thelial cells to anchorage independent growth, and knockdown causing significant reduction in
cancer cell survival [14]. MAGE-A3 knockdown in human multiple myeloma cell lines and pri-
mary cells resulted in apoptosis, and in this context it appeared to regulate p53-dependent and
independent survival mechanisms [11]. The biochemical basis for this activity appears to be
exerted through binding to and modulating the activities of RING domain containing E3 ubiqui-
tin ligases [15, 16]. Surprisingly, given the conservation within the MAGE family, the interaction
of various family members with specific RING domain containing proteins was not found to
involve the conserved RING domain. Rather, each MAGE protein appears to recognize a unique
region on its RING partner, suggesting that MAGE proteins are able to function as a versatile and
adaptable protein interaction module. MAGE-A3 was found to interact with the nuclear scaffold-
ing protein and E3 ligase TRIM28 (also known as KAP1), via its RING-B box coiled coil (RBCC)
motif [15], and this interaction was found to stimulate the E3 ligase activity leading to degrada-
tion of various targets with roles in apoptosis such as the tumour suppressor p53[15, 17], the
KRAB zinc finger transcription factor ZNF382[18], and the metabolic regulator AMP activated
protein kinase (AMPK)[14]. In contrast to MAGE-A3, relatively little is known about the possible
interactions of MAGE-A4 with RING containing ligases. Despite sharing 69% sequence identi-
ties, there is considerable evidence for a distinct and possibly contrasting roles for MAGE-A4 in
apoptosis and tumour cell proliferation, with the C-terminal region of MAGE-A4 has been found
to interact with gankyrin [19] and Miz-1 [20], and induce rather than suppress apoptosis.
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Early efforts to exploit MAGE proteins in cancer therapy have focussed on immunothera-
peutic approaches, culminating in two phase III clinical trials of a recombinant MAGE-A3 pro-
tein vaccine in melanoma and NSCLC [21]. The results of these trials were disappointing, as
they did not meet their primary endpoints. However, the revelation of class I MAGE proteins
as drivers of oncogenesis has opened the exciting potential to target the cellular function of
MAGE proteins in cancer therapy. To gain insights into the structural basis for the functional
differences between MAGE proteins and to provide a molecular framework for the rational
design of novel compounds targeting MAGE protein function, we have determined the crystal
structures of the MAGE homology domains of MAGE-A3 and MAGE-A4. Both proteins crys-
tallized in an unusual arrangement with extended terminal peptides sequences occupying a
cleft between the twoWH domains. Comparisons with other MAGE family members provide
insights into the function and utility of the MHD as a protein-protein interaction module and
allow us to suggest a possible strategy for MAGE inhibition based on compounds binding pref-
erentially to distinct conformational states. Finally we have re-examined previous structural
data of a complex between a MAGE protein and an E3 ligase, the MAGE-G1-NSE-1 complex,
and propose a possible alternative arrangement for the complex with distinct topological prop-
erties which offer possible new insights into MAGE family regulation and interaction.
Materials and Methods
Cloning and protein expression
Plasmid DNA templates for full-length humanMAGE-A3 (IMAGE id 3345801) andMAGE-A4
(IMAGE id 4394783) were obtained from the Mammalian Gene Collection (Source BioScience,
Nottingham, UK). Regions corresponding to the MHD domains of MAGE-A3 andMAGE-A4
(residues 104–314 and 101–317 respectively), and a C-terminally truncated version of MAGE-A3
(residues 104–294) were amplified by PCR. MAGEA4 fragments were cloned into vector
pNIC28-Bsa4, which appends a Tobacco Etch Virus (TEV) protease-cleavable His6 tag at the N-ter-
minal. MAGEA3 fragments were cloned into vector pNH-TrxT (GU269914) which appends a
TEV-cleavable His6-thioredoxin tag, as described elsewhere [22]. For overexpression, plasmids
were transformed into BL21 (DE3) Rosetta-R3, and cultures were grown in UltraYield baffled flasks
(Thomson Instrument Company, CA, USA) in terrific broth medium containing 50 μg/ml kana-
mycin, at a temperature of 37°C to an optical density of 2–3, at which point the cultures were cooled
to 18°C and expression was induced by addition of 0.3 mM Isopropyl β-D-1-thiogalactopyranoside,
cells were harvested 18hr after induction. For production of selenomethionine incorporated
MAGE-A4, cells were inoculated into 6x 10-ml of LBmedium containing 50 μg/ml kanamycin and
35 μg/ml chloramphenicol and grown overnight at 37°C. Cultures were harvested by centrifugation,
washed twice with M9minimal medium and resuspended in 10 ml of M9minimal medium. These
cultures were used to inoculate 1L of M9minimal medium, which was grown in 2.5L UltraYield
baffled flasks until OD600 of 0.80. Selenomethioine was added to 25mg/L along with leucine, isoleu-
cine and valine to 50mg/L and lysine, threonine, and phenylalanine to 100mg/L (all amino acids
dissolved in 0.2MHEPES pH 7.5). Cultures were grown for a further 1.5 hours until OD600 of 1.2
and then cooled to 18°C for 1 hour. Additional selenomethioine was added (final total concentra-
tion of 75mg/L). IPTG was added to 0.1 mM, and growth continued at 18°C overnight.
Protein Purification
For purification of both MAGE-A3 constructs cell pellets were thawed and resuspended in
buffer A (50 mMHEPES pH 7.5, 500 mMNaCl, 5% glycerol, 10 mM imidazole, 0.5 mM
TCEP) and disrupted by sonication. Cell debris and nucleic acids were removed by centrifuga-
tion at 50000 x g for 1 hour at 4°C. The supernatants were applied to a 3 ml Ni-IDA IMAC gravity
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flow column, washed with wash buffer (buffer A with 30 mM imidazole), and eluted with 5CV of
elution buffer (buffer A with 300mM imidazole). Proteins were incubated overnight at 4°c in the
presence of TEV protease (1:50 mass ratio) whilst being dialysed, using 3.5 kDaMWCO Snakeskin
membrane (Thermo Fisher Scientific, Rockford, IL, USA) into buffer B (20 mMHEPES, pH 7.5,
500 mMNaCl, 5% glycerol, 0.5 mM TCEP). TEV protease and contaminating proteins were
removed by reapplication of dialysed proteins to a Ni-IDA IMAC column (2 ml CV). Proteins
passing through the column were pooled and concentrated, using a 10 kDaMWCO centrifugal
concentrator, to 1ml before loading onto a HiLoad 16/60 Superdex S75 gel filtration column equili-
brated in buffer B. Fractions containing MAGE-A3 were pooled and diluted 10 fold in dH2O to 50
mMNaCl and applied to a 1ml Mono Q anion exchange column equilibrated in 50 mMHepes
pH 7.5, 50 mMNaCl. Proteins were eluted with a linear gradient to 50 mMHepes pH 7.5, 1M
NaCl over 30 CV, and fractions containing MAGE-A3 were pooled and concentrated.
MAGE-A4 was purified as for MAGE-A3 but with the omission of the TEV cleavage, Ni-IDA
rebind and anion exchange steps. In both cases proteins were identified by SDS PAGE, although
it was found that MAGE-A3 andMAGE-A4 showed unusual behaviour on SDS-PAGE, migrat-
ing as two bands connected by smearing with the proportion of the upper band being concentra-
tion dependant. This was found to be the case regardless of the construct boundaries or presence
or absence of a tag. The identity of both bands belonging to MAGE proteins was confirmed by
tryptic digestion andMS/MS analysis. Concentrations were determined by measurement at 280
nM (Nanodrop) using the calculated molecular mass and extinction coefficients.
Crystallization and Structure Determination
For crystallization, MAGE-A3 and MAGE-A4 were concentrated to 5 mg/ml and 9 mg/ml
respectively and sitting drop vapour diffusion crystallization trials were set up with a Mosquito
(TTP Labtech) crystallisation robot. Crystals of native MAGE-A4 were observed to grow at
4°C from conditions containing 2.6 M NaCl, 0.1 M Tris-HCl pH 8 and were cryoprotected by
transfer to a solution containing 20% (w/v) D-glucose prior to being loop mounted and
plunged into a pool of liquid nitrogen. Diffraction data was collected at Diamond light source
beamline I04, and processed using MOSFLM [23]. SeMet-substituted MAGE-A4 crystallized
in 0.3 M Na-malonate pH 7, 20% PEG 3350, 10% ethylene glycol and 0.1M Bis-Tris propane
pH 8.5, and crystals were cryo protected in a reservoir solution supplemented with 25% ethyl-
ene glycol. A two wavelength MAD data set was collected at the Swiss Light Source (SLS) on
beamline X10SA at λ = 0.9782 Å (peak) and 0.97105 Å (remote). Data were integrated in
MOSFLM[23], an SeMet positions located using SHELXD[24] and refined using program
autoSHARP[25]. The initial model was built using BUCCANEER[26] and extended and com-
pleted manually using COOT[27]. The final refinement was performed using the 2.3 Å native
dataset and the REFMAC[28] program to a final Rfactor = 24.3%, Rfree = 27.4%.
MAGE-A3 crystallized at 4°C in conditions containing 15% PEG 3350, 0.1MMg Formate,
and crystals were loop mounted and cryo protected in a reservoir solution supplemented with
25% ethylene glycol. Data were collected to 2.0Å resolution at Diamond light source beamline
I24, and processed using XDS[29]. The structure was solved by molecular replacement using
the program PHASER[30] and the structure of MAGE-A4 as a search model. Refinement was
performed using PHENIX REFINE[31] to a final Rfactor = 22.3%, Rfree = 23.4%. A full summary
of the data collection and refinement statistics are found in Table 1.
Small angle X-ray scattering
Small angle X-ray scattering measurements of MAGE-A3 in solution were performed at Dia-
mond light source beamline B21 using a BIOSAXS robot for sample loading. Measurements
Structures of Melanoma-Associated Antigen Proteins MAGEA3 and MAGEA4
PLOSONE | DOI:10.1371/journal.pone.0148762 February 24, 2016 4 / 20
were made using three different protein concentrations of 3.5, 1.75 and 0.88 mg/ml respectively
in a buffer comprising 10 mMHepes pH 7.5, 250 mMNaCl, 0.5 mM TCEP. The data were
reduced and buffer contributions subtracted with the DawnDiamond software suite and ana-
lysed using the program SCATTER (www.bioisis.net). Pairwise distance distribution P(r) func-
tions were calculated using GNOM[32] and compared to theoretical P(r) distributions from
model coordinates in calculated in SCATTER. Real space scattering profiles of atomic models
were calculated from atomic models using CRYSOL[33] and aligned and scaled to the experi-
mental data using PRIMUS[34].
Analytical ultracentrifugation
Sedimentation velocity AUC experiments were performed on a XL-I Analytical Ultracentrifuge
using a Ti-50 rotor and cells with double-sector centrepieces (Beckman Coulter, Brea, CA,
Table 1. Data collection and refinement statistics.
Data collection statistics
Se Met MAGE-A4 MAGE-A4 MAGE-A3
Space group P 65 2 2 P 65 2 2 P 61 2 2
Cell dimensions, a,b,c (Å) 81.5, 81.5, 210.6 81.6, 81.6, 210.9 61.5, 61.5, 292.8
Angles α,β,γ (°) 90, 90, 120 90, 90, 120 90, 90, 120
Wavelength (Å) 0.978 (pk) 0.971 (rm) 0.979 0.9686
Resolution (Å) 35.2–2.97 (3.13–2.97) 42–2.30 (2.42–2.30) 39–2.07 (2.18–2.13)
Rmerge 0.15 (1.17) 0.07 (0.54) 0.06 (1.11)
Rp.i.m. 0.07 (0.71) 0.03 (0.24) 0.03 (0.36)
I/σI 10.2 (1.1) 13.9 (2.2) 19.9 (2.2)
Completeness (%) 95.4 (78.4) 99.7 (99.1) 100 (100)
Multiplicity 6.5 (3.2) 6.4 (5.0) 10.2 (10.8)
No. Unique reﬂections 8866 (1014) 19314 (2718) 21270 (1612)
Reﬁnement statistics
MAGE-A4 MAGE-A3
Resolution 42–2.3 39–2.07
Rwork/Rfree (%) 24.2 / 27.4 20.0 / 23.8
No. atoms
Protein 1696 1663
Solvent 42 101
Ligand/ion 0 0
Average B factors (Å2)
All atoms 47.5 53.7
Protein 47.6 53.7
Solvent 41.8 54.0
Wilson B 57.4 43.3
R.M.S. deviations
Bond lengths (Å) 0.014 0.003
Bond angles (°) 1.41 0.761
Ramachandran plot
Favoured (%) 92.7 98.6
Allowed (%) 100 100
PDBid 2WA0 4V0P
Values in parenthesis are for the highest resolution shell
doi:10.1371/journal.pone.0148762.t001
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USA). Both MAGE-A3 and MAGE-A4 proteins were exhaustively dialysed against 10 mM
HEPES (pH 7.5), 150 mMNaCl, and 0.5 mM TCEP and filtered through a 0.22 μm syringe fil-
ter prior to analysis. Samples were studied at 0.75 mg/ml (MAGE-A3) and 0.5 mg/ml
(MAGE-A4) at 4°C, employing a rotor speed of 45,000 rpm. Absorbance data (280 nm) were
analysed with SEDFIT[35] calculating c(s) distributions using partial specific volumes and
buffer parameters calculated using the program SEDINTERP[36]. Theoretical sedimentation
coefficients of model proteins were calculated from atomic models using the program
HYDROPRO[37].
The structures reported here were deposited in the PDB, codes 2WA0 (MAGE-A4) and
4V0P (MAGE-A3).
Results and Discussion
Overall structure of the MAGE-A3 MHD domain
Crystals of the MAGE-A3 MHD domain were obtained using a construct spanning residues
104–314, and diffracted to 2.0 Å resolution at Diamond light source beamline I24. The struc-
ture was solved by molecular replacement using the experimentally phased structure of
MAGE-A4 as a search model. The electron density map is of overall excellent quality with the
entirety of the single molecule in the asymmetric unit being modelled with the exception of the
final 4 residues at the C-terminus, which were not included in the final model due to disorder.
The MHD domain structure consists of two highly modified winged helix WH domains WH1
andWH2 in a tandem arrangement linked by an extended β-hairpin (Fig 1A and 1B). Both
WH domains feature the characteristic helix turn helix motif, which packs against a 3 stranded
antiparallel β-sheet. Despite sharing no significant sequence homology, WH1 (residues 102–
182) and WH2 (residues 199–276) can be superposed with an approximate 3.3 Å RMSD, with
the biggest difference being the region connecting the second and third helices of the WH
domain (often referred to as the helix turn helix HTHmotif), which is of a compact helical
character in WH1 but more extended in WH2 where an additional β-hairpin is formed (Fig
1B). The twoWH domains are related by an approximate 160° rotation with a moderate inter-
face between the two domains being formed by a combination of the connecting extended β-
hairpin together with two additional α-helices from the C-terminus. The final 15 residues at
the C-terminus form an extended peptide, with a short section of 310 helix, which in the
MAGE-A3 crystals forms an extensive interaction with a neighbouring molecule related by
2-fold crystallographic symmetry (Fig 1B).
Overall structure of the MAGE-A4 MHD domain
Crystals of MAGE-A4 diffracted to 2.3 Å resolution at Diamond light source beamline I04, and
the structure was solved by two wavelength MAD using SeMet derivatized protein. The elec-
tron density map is of overall high quality with the exception of three loop regions (spanning
residues 171–175, 191–194 and 262–269) where the density was not of sufficient quality to
build a reliable model. As would be expected given they share 64% sequence identities the
MAGE-A4 structure is overall very similar to that of MAGE-A3 (1.48 Å RMSD over 209
aligned residues) with the relative positioning of the two domains being the same in both struc-
tures (Fig 1D). The most prominent difference between the two structures is the relative con-
formation of region between helices α5 and α6 (residues 230–241 on MAGE-A4) and the
positioning of the extended N and C termini (Fig 1D). In MAGE-A4 the C-terminus is more
closely associated with the rest of the molecule and forms a longer section of α-helix, which
packs against the first and third helices of WH1. In contrast, the N-terminus of MAGE-A4,
which includes 16 residues that were part of an uncleaved purification tag, is extended and
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forms an interface with neighbouring molecule related by crystal symmetry (Fig 1E). We note
that it was not possible to obtain crystals of MAGE- A3 or MAGE-A4 when these extended C
and N terminal sequences were removed, suggesting the interfaces are critical to the formation
of the crystals.
MAGE-A3 and MAGE-A4 peptide binding sites
Given that the function of MAGE family proteins is likely to be in mediating protein-protein
interactions in apoptosis, the finding of two separate instances of extended peptides binding to
a conserved cleft between the two domains suggests a possible functional role for this region.
Furthermore an analysis of this interface, and the nature of the contacts within it may provide
an ideal starting point for the rational structure based design of targeted compounds to inhibit
Fig 1. Structure of the MHD domain of MAGE-A3 andMAGE-A4. (A)Multiple sequence alignment of the
MHD domains of MAGE-A3, MAGE-A4 and MAGE-G1, with the secondary structure elements of MAGE-A3
shown above for reference. (B)Overall structure of MAGE-A3 with secondary structure elements labelled.
(C) Comparison of MAGE-A3WH1 (green) andWH2 (orange). (D) Comparison of MAGE-A3 (orange) and
MAGE-A4 (green). (E) Space filling representation of the arrangement of molecules in the MAGE-A4 crystals
which form open ended interfaces via the N-terminal peptide sequence.
doi:10.1371/journal.pone.0148762.g001
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MAGE cellular function, such compounds may be useful in treating the various forms of cancer
that are dependent on MAGE family proteins for their growth and survival. Despite the peptide
sequences from MAGE-A3 and MAGE-A4 having different polarity, they both occupy an
approximately equivalent position within a relatively deep groove formed between the two
WH domains (Fig 2A). In MAGE-A3 the interface area is ~1650 Å2 per monomer, consists of a
mixture of polar and non-polar residues, and includes 5 unique hydrogen bonds, 1 salt bridge
and two prominent aromatic residues, Tyr 301 and Trp 307, that protrude deep in the groove
and make extensive van der Waals interactions with hydrophobic residues (Fig 2A). In contrast
to the situation in MAGE-A3, the electron density for the N-terminal, peptide sequence in
MAGE-A4 is less well defined and the interpretation of the map in this region was more uncer-
tain with only part of the peptide being modelled. Nevertheless, it is possible to identify three
possible hydrogen bonds and two buried aromatic residue (Tyr -4 and Phe -3) (Fig 2B). Analy-
sis of the electrostatic surfaces and sequence conservation patterns (Fig 2C) reveals that the
chemical environment and residues forming the interface are quite different between the two
proteins, indicating that compounds targeting these sites would have the potential to be rela-
tively specific.
Quaternary structure of MAGE-A3 and MAGE-A4
Given the extensive nature of the interfaces created by the binging of the peptide sequences to
this cleft we have investigated the possibility that they may have biological relevance and con-
tribute towards oligomer formation in solution. In the case of MAGE-A4 this is unlikely since
the interface is formed from residues in a purification tag, which are not part of the biological
MAGE-A4 sequence. Analysis of MAGE-A4 on the PISA web service [38] indicates a mono-
mer in solution with none of the other crystal contacts being probable dimer interfaces. Analy-
sis of His tagged MAGE-A4 by size exclusion chromatography revealed an unusual behaviour
with a significant amount of the protein eluting at volumes consistent with species much
smaller than monomeric MAGE-A4, suggesting some kind of interaction with the column
media. We were able to prevent this behaviour with addition of 10% galactose or by cleaving
the tag, both of which resulted in peaks roughly consistent with monomeric species in solution
(Fig 3A). Analysis of cleaved MAGE-A4 constructs by sedimentation velocity analytical ultra-
centrifugation reveals a single species with sedimentation coefficient S of 1.46 (Sw
20 of 2.34)
(Fig 3B), consistent with a compact globular species with a molecular mass of 23360 ± 1937
Da, which matches very closely to the theoretical mass of MAGEA4, and the calculated hydro-
dynamic properties of the monomeric model (Sw
20 2.43) using the program HYDROPRO.
In contrast to MAGEA4, PISA analysis of MAGE-A3 identified two potential biologically
relevant dimer interfaces. In addition to the peptide interface detailed above (“dimer A”) a sec-
ond interface is formed almost entirely by interactions from the second WH domain. This
interface (“dimer B”) is only slightly less extensive (~1400 Å2 of interface area versus ~1650
Å2) and is formed by the extended β-hairpin connecting the twoWH domains, together with
the third helix on the secondWH domain (α6) and the extended loop regions immediately pre-
ceding and following it (Fig 4A). This interface is predominantly polar in nature and contains
12 unique hydrogen bonds, and one unique salt bridge (Arg 234 to Asp 236) (Fig 4B).
In order to determine the oligomeric state of MAGE-A3 in solution and to distinguish
between the two possible dimers, which may have similar hydrodynamic properties, we have
produced a truncated construct MAGE-A3104-294 lacking the final 20 residues at the C-termi-
nus of the crystallized construct. Analysis of either MAGE-A3 construct in solution by size
exclusion chromatography reveals an unusual concentration dependant behaviour, with higher
protein concentrations generally giving peaks consistent with greater apparent molecular
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masses (data not shown). Analysis of MAGE-A3 by sedimentation velocity analytical ultracen-
trifugation revealed that for both constructs a single compact globular species was present with
sedimentation coefficient of S = 1.968 (S20,w = 3.144) and S = 1.973 (S20,w = 3.153) respectively,
Fig 2. Interfaces of peptide sequences in the cleft betweenWH1 andWH2. (A) Surface representation of MAGE-A3 with the C-terminal peptide
sequence shown in the ball and stick representation. The box shows a close up view with polar contacts shown as dashed lines and key interface residues
labelled. (B) Surface representation of MAGE-A4 with the N-terminal peptide bound in the cleft, viewed from the same angle as in 2A. (C) Surface
representation of MAGE-A3 (left) and MAGE-A4 (right) coloured according to electrostatic potential ± 5 kT/e. Both structures are viewed from the same angle
as in 2A and 2B.
doi:10.1371/journal.pone.0148762.g002
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consistent in both cases with molecular masses of approximately 40 kDa (Fig 5A and 5B).
These values are also in good agreement with the calculated theoretical sedimentation coeffi-
cients for the MAGE-A3 dimers, S20w = 3.23 and 2.98 for dimer A and dimer B respectively,
and although the experimental values fall somewhere in between the two calculated values the
fact that a compact dimer is formed in the truncated construct strongly suggests that the dimer-
ization in solution is formed via the dimer B interface, since there is no possibility to form the
C-terminal dimer in this construct.
We have also performed an analysis of MAGE-A3 in solution by small angle X-ray scatter-
ing (SAXS). Data for the crystallized construct MAGE-A3104-314 collected at three different
protein concentrations reveal a significant concentration dependence to the Gunier region of
the scattering profile (Fig 5C), with the Gunier-based Rg decreasing by approximately 8 Å over
Fig 3. Analysis of MAGE-A4 in solution. (A)Gel filtration profiles of MAGE-A4 constructs with and without the N-terminal His tag, in the presence and
absence of galactose. The elution volumes of size standards used for calibration are marked with black arrows. The inset shows a typical SDS PAGE gel of
MAGE-A4 which shows two bands of approximately 25 and 45 kDa connected by a smear. (B) Analytical ultracentrifugation of cleaved MAGE-A4. The raw
absorbance data plotted as a function of radius and time is shown in the top panel, the centre panel shows the distribution of residuals from the fit of the
diffusion deconvoluted continuous distribution c(s) model, and the bottom panel shows the distribution of sedimentation coefficient values from the data fit.
doi:10.1371/journal.pone.0148762.g003
Fig 4. Structures of the two possible dimers present in the MAGE-A3 crystals. (A) Type A dimers linked by insertion of the C-terminal peptide into the
cleft betweenWH1 andWH2. (B) Type B dimers linked by the extended β-hairpin, the insert shows a detailed view of the interface with interacting residues
labelled and polar contacts shown as dashed lines.
doi:10.1371/journal.pone.0148762.g004
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Fig 5. Analysis of MAGE-A3 in solution. (A-B) Analytical ultracentrifugation of MAGE-A3 constructs with (A) and without (B) the C-terminal peptide
required to form type A dimers. The raw absorbance data plotted as a function of radius and time is shown in the top panel, the centre panel shows the
distribution of residuals from the fit of the diffusion deconvoluted continuous distribution c(s) model, and the bottom panel shows the distribution of
sedimentation coefficient values from the data fit. (C) Small angle X-ray scattering curves for MAGE-A3 (construct 104–314, containing the C-terminal
peptide), collected at three different protein concentrations show significant concentration dependence in the Guinier region. (D) Distance distribution
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a 4 fold dilution. To make best use of this data we have combined the scattering curves from
the two lowest protein concentrations using the data at q>0.1 from the higher concentration
sample to minimize noise at high q values (Fig 5D). This data can easily be transformed by
indirect Fourier transform to a distance distribution function p(r), with the reciprocal and real
space radius of gyration values broadly in agreement (Rg = 25.4 and 26.5 respectively). Com-
paring this data to the calculated data obtained using the monomeric MAGE-A3 (Fig 5E),
dimer A (Fig 5F) and dimer B (Fig 5G) models reveals a significantly better fit for dimer B than
either dimer A or monomer, when comparing either in reciprocal or real space (chi2 of 1.99
versus 4.94 or 2.6 respectively).
Taken together it is clear that MAGE-A3 is predominantly a dimer in solution and that
dimer corresponds to dimer B, although it is possible that at higher concentrations these
dimeric units may further associate via the C-terminal peptide to form larger open ended oligo-
mers. A comparison of the MAGE-A3 and MAGE-A4 structures in the dimerization interface
reveals a significantly different conformation of the loop between the α5 and α6, which is
extensively involved in the dimer interface in MAGE-A3 but in MAGE-A4 adopts conforma-
tion which would make significant steric clashes with its symmetry counterpart, explaining
why the same interface was not formed in MAGE-A4. Looking at the sequence in this region
two significant substitutions are present, E232D and D236H, which would likely cause the loss
of four hydrogen bonds and two salt bridges from the interface. A phylogenetic analysis of the
entire human MAGE family (Fig 6), reveals these residues are present only in the closest two
MAGE-A3 homologues, MAGE-A6 and MAGE-A2, indicating that the interface has arisen at
the relatively late stages of MAGE family evolution. Another feature common to MAGE-A4
and MAGE-A3 is an additional 100 amino acids N-terminal to the MHD domains, which are
thought to be predominantly unstructured and may contribute towards the oligomeric sate of
the full length protein in vivo.
Comparisons of MAGE-A3 and MAGE-A4 with MAGE-G1
The only other MAGE domain structure in the PDB to date is the structure of the MAGE-G1
NSE-1 complex [15]. Comparing this structure to both MAGE-A3 and MAGE-A4 reveals in
both cases that there are significant differences in the relative positioning of the WH1 and
WH2 domains, which in MAGE-G1 are more distantly separated, and do not share any signifi-
cant interface. Using WH1 as a guide, a domain rotation of approximately 170° and translation
of ~30Å would be required to put WH2 in the position adopted by MAGE-G1 (Fig 7A) with
the hinge region being part of the linker connecting WH1 and WH2. Taken individually, the
WH domains of MAGE-A3 and MAGE-A4 can be aligned to MAGE-G1 with R.M.S.D. values
of 1.3 Å and 1.0 Å for WH1, and 1.5 Å and 1.7 Å for WH2 respectively. The most prominent
difference lies in the loop regions of WH2, several of which are disordered in the MAGE-G1
structure (Fig 7B).
Given the fact that MAGE-G1 and MAGE-A3/4 share such a highly conserved core struc-
ture, it is interesting to speculate whether these structures are representative of two different
conformational states, “Open” and “Closed” forms respectively. An examination of the regions
of WH1 on MAGE-G1 that contribute towards the NSE-1 interface reveals that they are not
fully accessible in the “Closed” form structures, suggesting that a conformational change is
function P(r), calculated from the MAGE-A3 SAXS data, the main plot shows the fit of the P(r) function to the data with the distribution in the insert. (E-G)
Comparisons of the experimental SAXS data and theoretical SAXS curves calculated from the MAGE-A3 monomer (E), dimer A (F) and dimer B (G). The
main plot shows the fit in reciprocal space using the program CRYSOL[33], and the insert shows the fit in real space calculated with the program SCATTER
(www.biosis.net).
doi:10.1371/journal.pone.0148762.g005
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Fig 6. Sequence alignment of the MAGE homology domain of representative humanMAGE sequences. Sequences were aligned using CLUSTALX
and visualised with Jalview. Alignment numbering is according to MAGE-A4 residue number. Secondary structure is aligned to the MAGE-A4 structure, with
α-helices as red cylinders, β-strands as green arrows and 310 helices as purple cylinders. Residue conservation is represented by the histogram, with a
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required for MAGE–RING domain binding and that targeting the peptide binding groves with
compounds which bind to and stabilize preferentially the “Closed” conformation may be a
valid therapeutic route for cancer treatment.
An alternative model for the MAGE-G1 NSE-1 interface
We have noted while examining the MAGE-G1 NSE-1 complex structure that the linker region
connecting WH1 and WH2 was absent from the model and the electron density in this region
was poor. As the missing residues lie close to a crystallographic 2-fold symmetry axis, the ter-
mini of the various domains are positioned such that there are two alternative ways to connect
them (Fig 8A). To investigate which of these two possibilities is correct, and in the absence of
other experimental information, we have downloaded the structure factors and performed a
re-refinement of the structure, testing if the data support the alternative connectivity. Our re-
refined model has slightly improved refinement and geometry statistics, and we were able to
correct a number of minor model building errors in the original coordinates (Fig 9, Table 2).
Electron density maps covering the connecting region, (calculated omitting contributions from
residues in the linker region) show significant positive density features generally supporting
the alternative connection (Fig 8B), although we were unable to completely connect the two
domains in this way with 2 residues (163 and 164) being absent from the re-refined model.
Importantly for the biological interpretation of the interaction between MAGE-G1 and
NSE-1 (and MAGE RING interfaces in general), the re-refined interface between NSE-1 and
MAGE-G1 contains contributions from both the N and C-terminal WH domains. In the new
interface the N-terminal WH domain of NSE-1 is sandwiched between the twoWH domains
of MAGE-G1 with additional contacts coming from residues in the linker region and the C-ter-
minal WH domain WHB, some of which involve residues in the second WH domain of NSE-
1. Analysis of the interface by the PISA software identified an additional 385 Å2 of interface
area (1385 Å2 total), 11 additional hydrogen bonds and 7 additional salt bridges (Fig 8C). Sup-
port for this interpretation comes from the fact that the in vitro protein-protein interaction
data found that both the N and C terminal WH domains of MAGE-G1 were required for NSE-
scale from 0 (no conservation) to 9, with complete identity denoted by an asterisk. Residues E232 and D236 in the dimer interface of MAGEA3 (marked with
*) are found only in MAGEA3, MAGEA6 and MAGEA2; the corresponding residues in MAGEA3 are D233 and H237.
doi:10.1371/journal.pone.0148762.g006
Fig 7. Comparisons between MAGE-G1 and MAGE-A3/A4. (A) Comparison of the relative conformations of WH1 andWH2 in the MAGE-G1 structure
(open form) and in the MAGE-A3/A4 structures (closed form, shown as semi-transparent cartoons), the original connectivity is shown on the left and the re-
refined on the right hand side. (B) Superposition of the MAGE-A3 (orange), MAGE-A4 (green) and MAGE-G1 (pink) structures on the basis of the individual
WH1 andWH2 domains.
doi:10.1371/journal.pone.0148762.g007
Structures of Melanoma-Associated Antigen Proteins MAGEA3 and MAGEA4
PLOSONE | DOI:10.1371/journal.pone.0148762 February 24, 2016 14 / 20
1 binding [15]. On the other hand if the two WH domains are connected in this way, the sym-
metry at this position would mean that two of the MAGE-G1 NSE-1 complexes are almost cer-
tainly topologically interlinked in the crystals. Whilst this type of arrangement is not totally
unprecedented, it is difficult to imagine how the crystals were able to form and grow. One pos-
sible explanation is that the MAGE-G1 NSE-1 complex exists as a higher order oligomeric
Fig 8. Re-analysis of the MAGE-G1 NSE1model. (A) View of the original (red ribbon) and alternate (black
ribbon) choices around the crystallographic symmetry axis (shown as green lines). A single NSE-1 is shown
as grey spheres. (B) Electron density maps in the region connectingWH1 andWH2. The 2Fo-1Fc (blue) and
Fo-Fc (green) electron density maps (calculated with all atoms between 161 and 171 omitted from the model)
are shown contoured at 0.9 σ and 2.4 σ respectively with the domains coloured as for panel A. (C)
Comparison of the interfaces between the original (semi-transparent cartoon) and alternative (opaque
cartoon) MAGE-G1 models and NSE-1 (shown in the surface representation). The insert shows a detailed
view of the additional interface in the alternate model with interacting residues labelled and shown in the stick
format and polar contacts shown as dashed lines. (D) Possible MAGE-G1 NSE-1 hetero-tetramer found in
the MAGE-G1 NSE-1 crystallographic asymmetric unit with the two MAGE-G1 monomers (shown in green
and blue) topologically interlinked.
doi:10.1371/journal.pone.0148762.g008
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species in solution, possibly a heterotetramer (Fig 8D), which has an ordered pathway for addi-
tion of monomers. Alternatively it is a possibility that MAGE-G1 has been subjected to proteo-
lytic cleavage prior to or during the crystallization experiment. In this case the complexes are
not in fact interlinked and the lack of complete connecting density could be explained by the
cleavage event. Serendipitous proteolysis is not uncommon in crystallization and we are aware
of the power of the constraints of crystallization in selecting specifically for infrequent events.
In any case it would appear that additional experimentation may be required to resolve this
question.
Conclusions
In this study we present the first and third MAGE domain structures to be determined. The
two structures both show a tandem arrangement of modified WH domains, which form the
same relative positioning of the two domains and an overall high degree of structural similarity
(RMSD 1.5 Å). Surprisingly both proteins contained an extended peptide sequence bound
tightly to a groove formed between the two domains suggesting a possible biological role for
this region in protein-protein interactions.
The oligomeric state of the various MAGE proteins may also play a role in their function as
protein interaction modules in vivo. We have found MAGE-A4 to be a monomer in solution
whereas MAGE-A3 is a dimer, linked by an extensive interface that predominantly contains
residues fromWH2. The majority of the equivalent residues to those involved in the
Fig 9. Examination of physically unlikely features in the MAGE-G1 NSE-1 complex structure 3NW0.
(A) Zinc ion coordination in the NSE-1 structure by three cysteine residues and a histidine which clearly
needs to be rotated to make chemical sense. (B) Tryptophan sidechain which is truncated at Cβ in the 3NW0
model, with insufficient space for any of the possible rotamers (shown in a semi-transparent stick
representation) to be accommodated without significant steric clashes. (C-D) Large gaps in the structure with
distances incompatible with a single missing residue. Gaps are shown by dashed lines with distances and
residue registers labelled accordingly.
doi:10.1371/journal.pone.0148762.g009
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MAGE-G1 NSE-1 interface, are not part of the MAGE-A3 dimer, suggesting that binding and
dimerization need not be mutually exclusive.
We have also performed a re-examination of the crystal structure data on the MAGE-G1
NSE-1 complex and suggest an alternative way in which the N and C terminal WH domains of
MAGE-G1 can be connected. Importantly this configuration gives a significantly more exten-
sive interface for NSE-1 binding and is consistent with experimental data showing both WH
domains were required for full NSE-1 binding activity. A comparison of these various struc-
tures reveals that significant domain movements would be required to place the domains in the
same relative positions (regardless of whether the original or alternate arrangement of
MAGE-G1 is chosen for comparison).
One key aspect of MAGE domain function is the question of whether these domain rear-
rangements represent different functional states of the MAGE protein biological function. Sev-
eral of the regions that contribute to the MAGE-G1 NSE-1 interface are no longer solvent
accessible in the conformation adopted by free MAGE-A3 or MAGE-A4. This would suggest
that the “closed” conformations adopted by MAGE-A3 and MAGE-A4 to which peptide
sequences are bound would be incapable of forming, or require substantial rearrangements to
form associations with RING family members. This “conformational plasticity” between the
free and RING protein-bound states suggests selective and specific pharmaceutical strategies
that target conformation rather than enzymatic activity. Thus the peptide binding sites of
MAGE-A3 and MAGE-A4 may be important for MAGE regulation in vivo, and drug mole-
cules targeting these sites could potentially lock the MHD in the “closed” conformation, pre-
vent binding to their RING domain partners, and antagonize their proliferative and survival
activities in cancer cells.
Table 2. Refinement statistics for the original and re-refined MAGE-G1 NSE-1 structure.
Original Re-reﬁned
Resolution 40–2.75 # 32.3–2.92 #
Rwork/Rfree (%) 21.9/27.1 23.7/26.8
No. atoms
Protein 3516* 3532
Solvent 0 * 0
Ligand/ion 3 * 2
Average B factors (Å2)
Protein 110 100
Ligand/ion 107 74
Wilson B 111 90
R.M.S. deviations
Bond lengths (Å) 0.011 0.003
Bond angles (°) 1.523 0.69
Ramachandran plot
Favoured (%) 87.8 94.05
Allowed (%) 96.41 100
PDBid 3NW0 ?
# Reported resolution and statistics for the original MAGE-G1 NSE-1 data do not match the structure
factors uploaded to wwPDB entry 3NW0.
* Reported model contents do not match wwPDB entry 3NW0 (PDB entry contains 3476 protein atoms, 2
Zn2+ ions, 2 Mg2+ ions and 17 water molecules.
doi:10.1371/journal.pone.0148762.t002
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Supporting Information
S1 File. Validation report of MAGEA4 structure PDB:2WA0.
(PDF)
S2 File. Validation report of MAGEA4 structure PDB:4V0P.
(PDF)
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